Jubilant Life Sciences has received final USFDA approval for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug. The drug is a generic version of Symmetrel of Endo, which is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions. As on December 31, 2017, Jubilant Life Sciences had 86 ANDAs for oral solids filed in the US, of which 56 have been approved and 12 injectable filings, of which 10 had been approved.
Company Profile : Jubilant Life Sciences Ltd
Leave a Reply